Targeted, Orally Delivered Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its three proprietary therapeutic technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease, capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis, and adrulipase, a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by autoimmune malfunction. Disease targets include patient populations with digestive disorders, such as celiac disease, gastroparesis, exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis, and inflammatory bowel diseases such as ulcerative colitis.
IN THE NEWS
Mar 18, 2024
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
|
Mar 14, 2024
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
|
Mar 05, 2024
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
|